Abstract
There is a lack of real-world data on the use of omalizumab in treatment-refractory chronic spontaneous urticaria (CSU). A single-centre retrospective cohort study was performed to assess the efficacy and safety of omalizumab for treatment-refractory CSU. The overall response rate of 67% is comparable with that reported in the literature. Disease control and sustained remission can be achieved with omalizumab, even in patients with treatment-resistant CSU.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
